Number of the records: 1  

Current challenges in understanding the role of enhancers in disease

  1. 1.
    0567380 - ÚMG 2023 RIV US eng J - Journal Article
    Zaugg, J. B. - Sahlen, P. - Andersson, R. - Alberich-Jorda, Meritxell - de Laat, W. - Deplancke, B. - Ferrer, J. - Mandrup, S. - Natoli, G. - Plewczynski, D. - Rada-Iglesias, A. - Spicuglia, S.
    Current challenges in understanding the role of enhancers in disease.
    Nature Structural & Molecular Biology. Roč. 29, č. 12 (2022), s. 1148-1158. ISSN 1545-9993. E-ISSN 1545-9985
    EU Projects: European Commission(XE) 860002 - ENHPATHY
    Institutional support: RVO:68378050
    Keywords : beta-globin gene * shadow enhancers * burkitt-lymphoma * super-enhacers * single-cell * chromatin * expression * variants * identification * dissection
    OECD category: Biochemistry and molecular biology
    Impact factor: 16.8, year: 2022
    Method of publishing: Limited access
    https://www.nature.com/articles/s41594-022-00896-3

    Enhancers play a central role in the spatiotemporal control of gene expression and tend to work in a cell-type-specific manner. In addition, they are suggested to be major contributors to phenotypic variation, evolution and disease. There is growing evidence that enhancer dysfunction due to genetic, structural or epigenetic mechanisms contributes to a broad range of human diseases referred to as enhanceropathies. Such mechanisms often underlie the susceptibility to common diseases, but can also play a direct causal role in cancer or Mendelian diseases. Despite the recent gain of insights into enhancer biology and function, we still have a limited ability to predict how enhancer dysfunction impacts gene expression. Here we discuss the major challenges that need to be overcome when studying the role of enhancers in disease etiology and highlight opportunities and directions for future studies, aiming to disentangle the molecular basis of enhanceropathies.
    Permanent Link: https://hdl.handle.net/11104/0338881

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.